Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound 386, also known as Nourishing Liver and Kidney Compound or Yanggan Yishen Fang, is a Traditional Chinese Medicine (TCM) formulation developed by Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. It is currently being evaluated in clinical trials for the treatment of hepatitis B virus (HBV)-related decompensated cirrhosis. The compound is designed to improve overall survival and safety by addressing the TCM-defined deficiencies of the liver and kidney that occur during advanced chronic liver disease. As a multi-ingredient herbal therapy, it likely exerts its effects through multiple pathways, including anti-inflammatory and hepatoprotective mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nourishing Liver and Kidney Compound 386.